: Weekly infusion of bortezomib along with rituximab in relapsed/refractory indolent non-follicular as well as layer mobile lymphoma remains safe and secure and efficient: two-years analysis associated with stage Two trial BRIL06 regarding Intergruppo Italiano Linfomi (IIL) [abstract]. Bloodstream The year 2010, 116:1617a. 27. Baiocchi RA, Alinari #links# M, Lustberg Myself, Lin TS, Porcu S, Li Ti